Viking Therapeutics (VKTX) Gains from Sales and Divestitures: 2015-2025
Historic Gains from Sales and Divestitures for Viking Therapeutics (VKTX) over the last 11 years, with Sep 2025 value amounting to $744,017.
- Viking Therapeutics' Gains from Sales and Divestitures fell 52.03% to $744,017 in Q3 2025 from the same period last year, while for Sep 2025 it was $744,017, marking a year-over-year decrease of 52.03%. This contributed to the annual value of $1.6 million for FY2024, which is 97.55% up from last year.
- Per Viking Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $744,017 for Q3 2025, which was up 11.38% from $668,015 recorded in Q2 2025.
- Over the past 5 years, Viking Therapeutics' Gains from Sales and Divestitures peaked at $1.6 million during Q3 2024, and registered a low of $192,229 during Q1 2021.
- Its 3-year average for Gains from Sales and Divestitures is $945,710, with a median of $785,105 in 2023.
- In the last 5 years, Viking Therapeutics' Gains from Sales and Divestitures skyrocketed by 276.72% in 2021 and then tumbled by 52.03% in 2025.
- Quarterly analysis of 5 years shows Viking Therapeutics' Gains from Sales and Divestitures stood at $270,063 in 2021, then soared by 51.66% to $409,569 in 2022, then soared by 91.69% to $785,105 in 2023, then surged by 97.55% to $1.6 million in 2024, then plummeted by 52.03% to $744,017 in 2025.
- Its Gains from Sales and Divestitures stands at $744,017 for Q3 2025, versus $668,015 for Q2 2025 and $668,015 for Q1 2025.